March 18th 2023
The company also will establish a $35 cap on out-of-pocket costs for Lantus for all patients with commercial insurance.
January 23rd 2023
FDA Accepts Jardiance sNDA for CKD IndicationJanuary 23rd 2023
A phase 3 trial showed that Jardiance reduced the risk of kidney disease progression or cardiovascular death in adults with chronic kidney disease by 28% compared with placebo. An FDA decision is expected in the second half of 2023.
FDA Approves First Drug that Delays DiabetesNovember 18th 2022
Tzield addresses the underlying cause of the disease, where the immune system destroys the insulin producing cells in the pancreas. It will be available by the end of the year with a wholesale acquisition cost of $13,850 per vial.